Privium Fund Management B.V. Sells 250,999 Shares of BridgeBio Pharma, Inc. $BBIO

Privium Fund Management B.V. lessened its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 73.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 89,151 shares of the company’s stock after selling 250,999 shares during the quarter. BridgeBio Pharma makes up approximately 1.1% of Privium Fund Management B.V.’s portfolio, making the stock its 21st biggest holding. Privium Fund Management B.V.’s holdings in BridgeBio Pharma were worth $5,866,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the company. Silvant Capital Management LLC bought a new stake in shares of BridgeBio Pharma in the second quarter valued at $28,000. Allworth Financial LP bought a new position in shares of BridgeBio Pharma during the 2nd quarter worth $31,000. Root Financial Partners LLC bought a new position in shares of BridgeBio Pharma during the 3rd quarter worth $28,000. SBI Securities Co. Ltd. increased its holdings in BridgeBio Pharma by 55.3% in the 3rd quarter. SBI Securities Co. Ltd. now owns 441 shares of the company’s stock worth $29,000 after acquiring an additional 157 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in BridgeBio Pharma in the 2nd quarter worth about $44,000. Hedge funds and other institutional investors own 99.85% of the company’s stock.

BridgeBio Pharma Stock Up 0.0%

NASDAQ:BBIO traded up $0.02 during trading hours on Friday, hitting $74.29. 3,157,589 shares of the company’s stock traded hands, compared to its average volume of 2,854,998. The firm has a market cap of $14.47 billion, a P/E ratio of -24.44 and a beta of 0.97. BridgeBio Pharma, Inc. has a 52 week low of $60.55 and a 52 week high of $93.42. The business’s fifty day simple moving average is $69.76 and its two-hundred day simple moving average is $72.78.

BridgeBio Pharma (NASDAQ:BBIO) last announced its earnings results on Thursday, October 29th. The company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.12. The business had revenue of $353.17 million during the quarter, compared to the consensus estimate of $293.47 million. During the same quarter in the prior year, the company earned ($0.95) earnings per share. BridgeBio Pharma’s revenue was up 192.6% compared to the same quarter last year. On average, analysts expect that BridgeBio Pharma, Inc. will post -2.55 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on BBIO. JPMorgan Chase & Co. upped their price target on shares of BridgeBio Pharma from $100.00 to $111.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Wells Fargo & Company raised their price objective on shares of BridgeBio Pharma from $98.00 to $102.00 and gave the stock an “overweight” rating in a report on Tuesday, August 11th. Cantor Fitzgerald reiterated an “overweight” rating on shares of BridgeBio Pharma in a research note on Monday, October 5th. Citigroup lowered their target price on shares of BridgeBio Pharma from $94.00 to $91.00 and set a “neutral” rating on the stock in a report on Monday, October 19th. Finally, Piper Sandler increased their target price on BridgeBio Pharma from $115.00 to $120.00 and gave the stock an “overweight” rating in a research report on Monday, October 19th. Nineteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $104.26.

Insider Buying and Selling

In other BridgeBio Pharma news, CAO Maricel Apuli sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, October 30th. The shares were sold at an average price of $72.85, for a total value of $145,700.00. Following the completion of the transaction, the chief accounting officer owned 120,687 shares of the company’s stock, valued at $8,792,047.95. The trade was a 1.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Neil Kumar sold 34,980 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $82.53, for a total transaction of $2,886,899.40. Following the completion of the transaction, the chief executive officer owned 243,327 shares of the company’s stock, valued at $20,081,777.31. This trade represents a 12.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 56,980 shares of company stock valued at $4,563,699. Corporate insiders own 14.23% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for genetically driven diseases. The company operates through a portfolio of subsidiary and affiliated biotechnology businesses, with research programs spanning rare diseases, oncology, cardiology and other conditions linked to underlying genetic or molecular causes.

BridgeBio’s portfolio includes therapies designed to address the root mechanisms of disease rather than primarily treating symptoms.